Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2(+) Breast Cancers: Implications to the ExteNET Trial
- 浏览0
Clinical cancer research
771-783页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



